Персона:
Блинова, Екатерина Валериевна

Научные группы

Научная группа

Организационные подразделения

Организационная единица

Инженерно-физический институт биомедицины

Цель ИФИБ и стратегия развития – это подготовка высококвалифицированных кадров на базе передовых исследований и разработок новых перспективных методов и материалов в области инженерно-физической биомедицины. Занятие лидерских позиций в биомедицинских технологиях XXI века и внедрение их в образовательный процесс, что отвечает решению практикоориентированной задачи мирового уровня – диагностике и терапии на клеточном уровне социально-значимых заболеваний человека.

Фамилия

Блинова

Имя

Екатерина Валериевна

Полная страница элемента

Результаты поиска

Теперь показываю 1 - 10 из 14

Открытый доступ
Clinical Anatomy of the Ligaments of the Face and Their Fundamental Distinguishing Features
(2024) Mirontsev, A.; Andruschenko, O.; Vasil’ev, Y.; Blinova, E.; Миронцев, Артём Владимирович; Блинова, Екатерина Валериевна
Our study aimed to clarify the anatomical features of the zygomatic, upper masseteric, lower masseteric and mandibular ligaments and their possible contribution to age-related gravitational ptosis. The study was carried out by the method of layered dissection of fresh cadavers. In several observations, the zygomatic ligament is represented by the fibers originating from the zygomaticus major muscle fibers. It is a true ligament with the fibers inserted directly into the skin. The upper and lower masseteric ligaments originate from the parotideomasseteric fascia and weave into the thickness of the SMAS. The mandibular ligament consists of two connective tissue laminae originating from the parotideomasseteric fascia at the lower edge of the mandible and from the inner surface of this fascia, along the anterior edge of the masseter muscle, skirting the facial vein sheath and the facial artery, traveling toward the platysma and the depressor anguli oris muscle, and merging with their fibers. The zygomatic ligament should be considered an osteo-musculocutaneous ligament, emphasizing the role of the associated zygomaticus major muscle in the mechanism of aging. The upper and lower masseteric and mandibular ligaments are false fascio-SMAS ligaments rather than osteo-cutaneous ones, playing the barrier role and fixing the superficial fascia and the platysma muscle.
Открытый доступ
An effective way for targeting EGFR-mediated carcinogenesis: an in vitro study
(2024) Pakina, V. A.; Epishkina, A. A.; Grebenkin, E. V.; Blinova, E. V.; Епишкина, Анна Алексеевна; Гребенкин, Евгений Валерьевич; Блинова, Екатерина Валериевна
Introduction: EGFR-activating overexpression or somatic mutations are common in different human cancers. In this regard, the search for promising ways to control the carcinogenic transformation of tumor cells and the progression of malignant tumors expressing EGFR seems to be one of the most promising and developing areas of modern molecular pathology and pharmacology. Material and Methods: An antitumor activity of a novel compound, a pyridine carboxylic acid derivative LHT-17-19, was studied. The molecule was developed and synthesized at the Department of Chemistry, Drug Design and Technology of All-Russian Research Center for Biological Active Compounds Safety (Russia). The study was carried out in cell cultures of stomach cancer (Hs746T, AGS and MKN1) and patient-derived organoid (PDO) model of breast cancer (BC) expressing wild-type EGFR. Results: It was shown that LHT-17-19 induced concentration-dependent cytotoxicity of EGFR-expressing gastric cancer cells of all the aforementioned cultures. Pathomorphological, immunohistochemical and molecular validation of BC organoids derived from ductal breast carcinoma cells of a 68-year-old patient was done. PDOs were established as ER-negative, PR-negative, Her2/neu-negative, EGFR-positive with 35% of the Ki-67 expression index. In addition, the tumor cells translocation was resulted in a loss of ER expression and PDOs molecular pattern conversion towards a more aggressive triple negative type. PDOs incubation with 0.5-60.0 ‚?M LHT-17-19 was accompanied not only by inhibition of their growth and proliferation, but also by significant cytoreduction. Conclusion: Thus, in two-dimensional and three-dimensional tumor cell cultures, the possibility of controlling the oncogenic expression of EGFR with the acridone compound 9-ammonium-3,3-dimethyl-3,4-dihydroacridine-1(2H)-OH L-2-hydroxybutanedivacate (LHT-17-19) was shown.
Только метаданные
Antitumor activity of aminochromene derivative on the human-derived lung adenocarcinoma xenograft model in BALB/C nu/nu mice IÐIOEAIIIOOIEAAIA AAENOAEA IÐIECAIAIIAI AIEIIOÐIIAIA IA IIAAEE ENAIIAÐAOOA AAAIIEAÐOEIIIU EAAEIAI O IUØAE nu/nu BALB
(2021) Dudina, M. O.; Blinov, D. S.; Suslova, I. R.; Skachilova, S. Ya.; Blinova, E. V.; Блинова, Екатерина Валериевна
© 2021 Izdatel'stvo Meditsina. All rights reserved.The antitumor and anti-metastatic effects of aminochromene derivative AKh-554 upon intragastric administration were studied on immunodeficient BALB/c nu/nu female mice with heterotopic human-derived lung adenocarcinoma xenograft model. In the tumor tissue of animals treated with the test compound, the levels of TUBB3, ALK and c-MET/HFG oncomarkers were quantitatively detected and it was found that the drug suppressed the velocity of tumor growth and its size as well as exhibited anti-metastatic activity. AKh-554 produced 3.3-fold increase in tumor carriers survival and induced stable remission in 60% of test mice (p 0.001). The effect might be due to anti-ALK-dependent activation of apoptosis of tumor cells and suppression of cell proliferation. The results were obtained on the tumor system without signs of pharmacoresistance to AX-554, which was confirmed by the lack of dynamics of c-MET/HFG in tumor tissue in all test groups.
Открытый доступ
Cerium-containing n-acetyl-6-aminohexanoic acid formulation accelerates wound reparation in diabetic animals
(2021) Pakhomov, D.; Shimanovsky, D.; Kilmyashkina, M.; Mazov, Y.; Blinova, E.; Блинова, Екатерина Валериевна
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.Background: The main goal of our study was to explore the wound-healing property of a novel cerium-containing N-acethyl-6-aminohexanoate acid compound and determine key molecular targets of the compound mode of action in diabetic animals. Methods: Cerium N-acetyl-6-aminohexanoate (laboratory name LHT-8-17) as a 10 mg/mL aquatic spray was used as wound experimental topical therapy. LHT-8-17 toxicity was assessed in human skin epidermal cell culture using (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A linear wound was reproduced in 18 outbred white rats with streptozotocin-induced (60 mg/kg i.p.) diabetes; planar cutaneous defect was modelled in 60 C57Bl6 mice with streptozotocin-induced (200 mg/kg i.p.) diabetes and 90 diabetic db/db mice. Firmness of the forming scar was assessed mechanically. Skin defect covering was histologically evaluated on days 5, 10, 15, and 20. Tissue TNF-α, IL-1β and IL-10 levels were determined by quantitative ELISA. Oxidative stress activity was detected by Fe-induced chemiluminescence. Ki-67 expression and CD34 cell positivity were assessed using immunohistochemistry. FGFR3 gene expression was detected by real-time PCR. LHT-8-17 anti-microbial potency was assessed in wound tissues contaminated by MRSA. Results: LHT-8-17 4 mg twice daily accelerated linear and planar wound healing in animals with type 1 and type 2 diabetes. The formulated topical application depressed tissue TNF-α, IL-1β, and oxidative reaction activity along with sustaining both the IL-10 concentration and antioxidant capacity. LHT-8-17 induced Ki-67 positivity of fibroblasts and pro-keratinocytes, upregulated FGFR3 gene expression, and increased tissue vascularization. The formulation possessed anti-microbial properties. Conclusions: The obtained results allow us to consider the formulation as a promising pharmacological agent for diabetic wound topical treatment.
Только метаданные
Expression of p53 protein associates with anti-pd-l1 treatment response on human-derived xenograft model of gata3/cr5/6-negative recurrent nonmuscular invasive bladder urothelial carcinoma
(2021) Samishina, E.; Deryabina, O.; Blinov, D.; Roshchin, D.; Blinova, E.; Блинова, Екатерина Валериевна
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.Background: The possible involvement of p53 signaling, FGFR3 expression, and FGFR3 mutation rates in the prediction of the NMIBC anti-PD-L1 treatment response needs to be clarified. The main aim of our study was to explore predictive value of p53 expression, FGFR3 expression, and its gene mutation status for the therapeutic success of anti-PD-L1 treatment in the patient-derived murine model of recurrent high-PD-L1(+) GATA3(-)/CR5/6(-) high-grade and low-grade NMIBC. Methods: twenty lines of patient-derived xenografts (PDXs) of relapsed high-PD-L1(+) double-negative NMIBC were developed, of which 10 lines represented high-grade tumors and the other ones—low-grade bladder cancer. Acceptors of each grade-related branch received specific anti-PD-L1 antibodies. Animals’ survival, tumor-doubling time, and remote metastasis were followed during the post-interventional period. PD-L1, GATA3, CR5/6, and p53 protein expressions in engrafted tumors were assessed by immunohistochemistry. The FGFR3 expression and FGFR3 mutations in codons 248 and 249 were detected by real-time polymerase chain reaction. Results: The expression of p53 protein is an independent factor affecting the animals’ survival time [HR = 0.036, p = 0.031] of anti-PD-L1-treated mice with low-grade high-PD-L1(+) double-negative NMIBC PDX. The FGFR3 expression and FGFR3 mutation rate have no impact on the anti-PD-L1 treatment response in the interventional groups. Conclusions: p53 expression may be considered as a prognostic factor for the anti-PD-L1 treatment efficacy of low-grade high-PD-L1-positive GATA3(-)/CR5/6(-)relapsed noninvasive bladder cancer.
Только метаданные
Novel Hydroxypyridine Compound Protects Brain Cells against Ischemic Damage In Vitro and In Vivo
(2022) Blinova, E.; Vasilkina, O.; Belanov, K.; Zalogin, S.; Blinov, D.; Блинова, Екатерина Валериевна
A non-surgical pharmacological approach to control cellular vitality and functionality during ischemic and/or reperfusion-induced phases of strokes remains extremely important. The synthesis of 2-ethyl-6-methyl-3-hydroxypyridinium gammalactone-2,3-dehydro-L-gulonate (3-EA) was performed using a topochemical reaction. The cell-protective effects of 3-EA were studied on a model of glutamate excitotoxicity (GluTox) and glucose-oxygen deprivation (OGD) in a culture of NMRI mice cortical cells. Ca2+ dynamics was studied using fluorescent bioimaging and a Fura-2 probe, cell viability was assessed using cytochemical staining with propidium iodide, and gene expression was assessed by a real-time polymerase chain reaction. The compound anti-ischemic efficacy in vivo was evaluated on a model of irreversible middle cerebral artery (MCA) occlusion in Sprague-Dawley male rats. Brain morphological changes and antioxidant capacity were assessed one week after the pathology onset. The severity of neurological disorder was evaluated dynamically. 3-EA suppressed cortical cell death in a dose-dependent manner under the excitotoxic effect of glutamate and ischemia/reoxygenation. Pre-incubation of cerebral cortex cells with 10–100 µM 3-EA led to significant stagnation in Ca2+ concentration in a cytosol ([Ca2+]i) of neurons and astrocytes suffering GluTox and OGD. Decreasing intracellular Ca2+ and establishing a lower [Ca2+]i baseline inhibited necrotic cell death in an acute experiment. The mechanism of 3-EA cytoprotective action involved changes in the baseline and ischemia/reoxygenation-induced expression of genes encoding anti-apoptotic proteins and proteins of the oxidative status; this led to inhibition of the late irreversible stages of apoptosis. Incubation of brain cortex cells with 3-EA induced an overexpression of the anti-apoptotic genes BCL-2, STAT3, and SOCS3, whereas the expression of genes regulating necrosis and inflammation (TRAIL, MLKL, Cas-1, Cas-3, IL-1β and TNFa) were suppressed. 3-EA 18.0 mg/kg intravenous daily administration for 7 days following MCA occlusion preserved rats’ cortex neuron population, decreased the severity of neurological deficit, and spared antioxidant capacity of damaged tissues. 3-EA demonstrated proven short-term anti-ischemic activity in vivo and in vitro, which can be associated with antioxidant activity and the ability to target necrotic and apoptotic death. The compound may be considered a potential neuroprotective molecule for further pre-clinical investigation. © 2022 by the authors.
Только метаданные
Experimental postoperative skin wound healing after Z-grafting followed by local application of cerium-containing N-acetyl-6-aminohexanoic acid compound
(2022) Galichenko, K. A.; Blinova, E.; Блинова, Екатерина Валериевна
Только метаданные
3-HYDROXYPYRIDINE DERIVATIVE WITH ASCORBIC ACID RESIDUE INCREASES SURVIVAL OF CEREBRAL CORTEX CELLS UNDER CONDITIONS OF EXPERIMENTAL ISCHEMIA IÐIECAIAIIA 3-AEAÐIENEIEÐEAEIA N INOAOEII ANEIÐAEIIAIE EENEIOU IIAUØAAO AUÆEAAAIINOU EEAOIE AIEIAIIAI IICAA A ONEIAEßO YENIAÐEIAIOAEUIIE EØAIEE
(2023) Blinova, E. V.; Timoshkin, D. E.; Belanov, K. Y.; Vasilkina, O. V.; Блинова, Екатерина Валериевна
Только метаданные
Buccal fat pad’ buccal flap anatomical variation
(2023) Mirontsev, A. V.; Kolesova, L. Yu.; Vasil’ev, Yu. L.; Blinova, E. V.; Миронцев, Артём Владимирович; Блинова, Екатерина Валериевна
Только метаданные
Clinical and experimental rationale for using phenylephrine with hypromellose for the treatment of extra accommodation strain in patients with myopia
(2023) Makhova, M. V.; Shikh, E. V.; Strakhov, V. V.; Blinova, E. V.; Blinov, D. S.; Блинова, Екатерина Валериевна